康艾注射液联合FOLFOX化疗方案治疗结直肠癌的临床研究

目的 探究康艾注射液与FOLFOX化疗方案联合治疗结直肠癌的疗效、不良反应以及对肿瘤标志物和免疫细胞的影响.方法 回顾性分析手术后行FOLFOX化疗方案治疗的100例结直肠癌患者,根据治疗方案不同将患者分为化疗组(接受FOLFOX化疗方案治疗)与联合组(接受康艾注射液联合FOLFOX化疗方案治疗),每组各50例.观察两组患者治疗后的临床治疗效果及不良反应发生情况,同时检测两组患者治疗前后肿瘤标志物和免疫细胞变化情况.结果 联合组患者的总缓解率明显高于化疗组(P﹤0.01);治疗后,两组患者的癌胚抗原(CEA)、CA19-9、CA242和CA724水平均较本组治疗前降低(P﹤0.05),免疫细胞CD3+、CD4+和CD4+/CD8+水平均较本组治疗前升高(P﹤0.05);治疗后,联合组患者的CEA、CA19-9、CA242和CA724水平均低于化疗组(P﹤0.05),免疫细胞CD3+、CD4+和CD4+/CD8+水平均高于化疗组(P﹤0.05).结论 康艾注射液与FOLFOX化疗方案联合治疗提高了结直肠癌患者的临床治疗效果和免疫功能,同时降低了患者的肿瘤标志物水平和不良反应发生率.

Clinical research of Kang'ai injection combined with FOLFOX chemotherapy in the treatment of colorectal cancer

Objective To observe the curative effect, adverse reaction, and the effect on tumor markers and immune cells of Kang'ai injection combined with FOLFOX chemotherapy in the treatment of colorectal cancer. Method 100 pa-tients with colorectal cancer treated by FOLFOX chemotherapy after surgery were retrospectively analyzed, and were as-signed into chemotherapy group (treated with FOLFOX chemotherapy) and combined therapy group (treated with FOLF-OX chemotherapy and Kang'ai injection), with 50 cases in each. The curative effect and adverse reactions of the two groups after treatment were observed, besides, the changes of tumor markers and immune cells before and after treatment were detected. Result The remission rate of the combined therapy group was significantly higher than that of the chemo-therapy group (P<0.01);after treatment, the carcinoembryonic antigen (CEA), CA19-9, CA242, and CA724 of the two groups were reduced as compared with before treatment (P<0.05), while CD3+, CD4+, and CD4+/CD8+ level were in-creased (P<0.05); after treatment, CEA, CA19-9, CA242, and CA724 in the combined therapy group were lower than those in the chemotherapy group, while CD3+, CD4+, and CD4+/CD8+were higher than that in the chemotherapy group af-ter treatment (P<0.05). Conclusion Kang'ai injection combined with FOLFOX chemotherapy can improve the clinical treatment effect and immune function of patients with colorectal cancer, and reduce the adverse reactions and level of tu-mor markers.